Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Soc Trans. 2010 Feb;38(Pt 1):137-43. doi: 10.1042/BST0380137.

The therapeutic potential of deubiquitinating enzyme inhibitors.

Author information

1
Hybrigenics SA, 3-5 Impasse Reille, 75014 Paris, France. fcolland@hybrigenics.com

Abstract

Proteases play a key role in various pathological processes and several protease inhibitors are already available for treatment. DUBs (deubiquitinating enzymes) constitute one of the largest classes of human proteases and are key effectors of the ubiquitin-proteasome system. This pathway regulating cellular protein turnover has been implicated in the pathogenesis of many human diseases, including neurodegenerative disorders, viral diseases and cancer. The therapeutic efficacy of the proteasome inhibitor Velcade (bortezomib) for treating multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. A promising alternative to targeting the proteasome itself would be to target the upstream, ubiquitin conjugation/deconjugation system, to generate more specific, less toxic anticancer agents. Advances in small molecule-based inhibitors specifically targeting DUBs are presented in this review.

PMID:
20074048
DOI:
10.1042/BST0380137
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center